Location History:
- Kirkland, CA (2014)
- Quebec, CA (2016)
Company Filing History:
Years Active: 2014-2016
Title: Martin Loignon: Innovator in Large-Scale Transfection Technologies
Introduction
Martin Loignon is a prominent inventor based in Quebec, Canada, known for his significant contributions to biotechnology, particularly in the field of large-scale transfection. With two patents to his name, Loignon has established himself as a key figure in the development of advanced processes and systems for protein production in mammalian cells.
Latest Patents
Loignon’s latest patents focus on processes, vectors, and engineered cell lines designed to enhance large-scale transfection and protein production. These patents describe methodologies primarily involving Chinese Hamster Ovary (CHO) cells, where transfection efficiencies are optimized through innovative techniques. Key elements of his patents include the utilization of a single vector system, functional oriP sequences in all plasmids, and codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs. Furthermore, his patents highlight the use of a fusion protein combining a truncated EBNA1c protein with a herpes simplex virus protein (VP16), and the employment of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent. Additionally, the co-expression of fibroblast growth factor (FGF) and protein kinase B enhances heterologous gene expression, contributing to innovative advancements in the field.
Career Highlights
Martin Loignon is actively engaged with the National Research Council of Canada, where he conducts research focused on biotechnological innovations. His work has important implications for the production of therapeutic proteins and vaccines, aiding the progress in medicine and biotechnology.
Collaborations
Throughout his career, Loignon has collaborated with esteemed colleagues, including Yves Durocher, to push the boundaries of transfection technologies. Together, they have worked on projects that aim to improve the efficiency and scalability of protein production processes, paving the way for breakthroughs in biopharmaceuticals.
Conclusion
Martin Loignon’s inventive spirit and dedication to enhancing large-scale transfection methodologies mark him as a leader in biotechnology. His contributions not only advance the field but also benefit future biomedical applications. As he continues to innovate within the National Research Council of Canada, the impact of his work is expected to grow, further solidifying his position as a significant figure in the world of biotechnology and patent innovation.